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and Franche Comté, Dijon, France
e Department of Radiation Oncology, Baclesse Cancer Center, Caen, GORTEC/intergroupe ORL, France
f Department of Neurology, Colmar Civil Hospital, Colmar, ANOCEF-IGCNO, France
g Department of Medical Oncology, Curie Institut, Saint-Cloud, France
h Department of Digestive Oncology, CHU Reims, Reims, FFCD, France
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Ingénierie Cellulaire et Génique, Department of Medical Oncology, University Hospital of Besancon, ARCAGY-GINECO,
Besancon, France
s Department of Medical Oncology, Gustave Roussy Cancerology Institute, Villejuif, ARCAGY-GINECO, France
t Department of Radiation Oncology,Vaud University Hospital Center (CHUV), Lausanne, GORTEC/intergroupe ORL,
Switzerland
u Department of Head and Neck Oncology, Gustave Roussy Cancerology Institute, Villejuif, GORTEC/intergroupe ORL,
France
v Cancerology Institut -Centre Jean Bernard-Clinique Le Mans, GORTEC/intergroupe ORL, France
w Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux
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ImmunotherapyAbstract Background: Cancer patients are thought to have an increased risk of developing
severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this
work, predictive factors for COVID-19 severity and mortality in cancer patients were investi-
gated.
Patients and methods: In this large nationwide retro-prospective cohort study, we collected
data on patients with solid tumours and COVID-19 diagnosed between March 1 and 11th
June 2020. The primary end-point was all-cause mortality and COVID-19 severity, defined
as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death,
was one of the secondary end-points.
Results: From April 4 to 11th June 2020, 1289 patients were analysed. The most frequent can-
cers were digestive and thoracic. Altogether, 424 (33%) patients had a severe form of COVID-
19 and 370 (29%) patients died. In multivariate analysis, independent factors associated with
death were male sex (odds ratio 1.73, 95%CI: 1.18e2.52), The Eastern Cooperative Oncology
Group Performance Scale (ECOG PS)  2 (OR 3.23, 95%CI: 2.27e4.61), updated Charlson
comorbidity index (OR 1.08, 95%CI: 1.01e1.16) and admission to ICU (OR 3.62, 95%CI
2.14e6.11). The same factors, age along with corticosteroids before COVID-19 diagnosis,
and thoracic primary tumour site were independently associated with COVID-19 severity.
None of the anticancer treatments administered within the previous 3 months had any effect
on mortality or COVID-19 severity, except for cytotoxic chemotherapy in the subgroup of pa-
tients with detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by
reverse transcriptase polymerase chain reaction (RT-PCR), which was associated with a slight
increase of the risk of death (OR 1.53; 95%CI: 1.00e2.34; p Z 0.05). A total of 431 (39%) pa-
tients had their systemic anticancer treatment (such as chemotherapy, targeted or immune
therapy) interrupted or stopped following diagnosis of COVID-19.
Conclusions: Mortality and COVID-19 severity in cancer patients are high and are associated
with general characteristics of patients. We found no deleterious effects of recent anticancer
treatments, except for cytotoxic chemotherapy in the RT-PCR-confirmed subgroup of pa-
tients. In almost 40% of patients, the systemic anticancer therapy was interrupted or stopped
after COVID-19 diagnosis.
ª 2020 Elsevier Ltd. All rights reserved.
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The Coronavirus Disease 2019 (COVID-19) outbreak,
caused by severe acute respiratory syndrome coronavi-
rus (SARS-CoV-2), has spread rapidly around the
world. Cancer patients were considered particularly
vulnerable to this disease due to immunosuppression
linked not only to the underlying malignancy and/or the
anticancer treatments, but also to the advanced age,
comorbidities and poor performance status or malnu-
trition frequently found in these patients. This vulnera-
bility was suggested by small retrospective studies [1,2],
and a meta-analysis reported an overall pooled preva-
lence of cancer of 2% in patients with COVID-19 [3].
Other studies have suggested that patients with cancer
have more severe forms of COVID-19 and higher mor-
tality than do patients without cancer [2,4e6]. However,
given the discordant data currently available, the impact
of anticancer treatments on COVID-19 severity remains
unclear, and there is little in the way of evidence-based
data to underpin changes in anticancer treatments
made during the peak of the pandemic [1,6e10]. It is
therefore necessary to analyse large cohorts of cancer
patients to better understand the course of COVID-19
and the factors likely to have an impact on its severity.
On 3rd April 2020 and through the French national
network of academic cooperative oncology groups in
solid cancers such as ANOCEF-IGCNO, ARCAGY-
GINECO, FFCD, GERCOR, GORTEC with inter-
groupe ORL,AND IFCT, we set up a large nationwide
cohort of solid-tumour cancer patients diagnosed with
COVID-19 since March 1. The aims of this cohort study
(named GCO-002 CACOVID-19) were to describe
clinical and tumour characteristics as well as outcomes
in cancer patients with COVID-19, to identify risk fac-
tors associated with severity and mortality, in particular
concerning active anticancer treatment, and to deter-
mine the consequences of the COVID-19 pandemic on
the management of cancer care.2. Materials and methods
2.1. Study design
The GCO-002 CACOVID cohort is a French observa-
tional nationwide multicentre cohort, set up by the
Groupes Coopérateurs en Oncologie (GCO), a French
consortium of academic cooperative groups in
oncology, including ANOCEF-IGCNO (Association
des Neuro-OnCologues d’Expression Française/Inter-
Groupe Coopérateur de Neuro-Oncologie) for central
nervous system (CNS) tumours, ARCAGY-GINECO
(Association de Recherche sur les CAncers
GYnecologiques-Groupes d’Investigateurs Nationaux
pour l’étude des CAncers Ovariens et du Sein) forgynaecological and breast cancers, FFCD (Fédération
Francophone de Cancérologie Digestive) for digestive
cancers, GERCOR (Groupe Coopérateur Multi-
disciplinaire en Oncologie), GORTEC (Groupe
d’Oncologie Radiothérapie Tête et Cou) with the
Intergroupe ORL for head and neck cancers (H&N) and
IFCT (Intergroupe Francophone de Cancérologie
Thoracique) for thoracic cancers.
The study was approved by the Research Ethics
Committee of Caen Normandy University Hospital for
all participating centres (Ref: 04/2020/MOR) and ob-
tained the authorisation of the National Commission for
Data Protection and Liberties (Ref CNIL: MLD/MFI/
AR204586). It was registered on ClinicalTrial.gov
(NCT04397575). In accordance with French regulatory
laws, all analysed patients were informed and those
not agreeing for the use of their clinical data were
excluded.2.2. Patients
The inclusion criteria were patients with a histologically
confirmed solid malignant tumour and a diagnosis of
COVID-19. Patients undergoing anticancer treatments
or treated curatively more than 5 years previously were
excluded. The diagnosis of COVID-19 was based on the
confirmation of SARS-CoV-2 infection by quantitative
RT-PCR on nasopharyngeal swabs, and/or imaging
features consistent with COVID-19 pneumonia on CT-
scan or based on highly suggestive symptoms combined
with positive severe acute respiratory syndrome coro-
navirus (SARS-CoV-2) serology. Patients with sugges-
tive symptoms of COVID-19 without a RT-PCR, CT-
scan or serological confirmation during the study period
were excluded from the analysis. Patients were included
in the cohort on the basis of clinicians’ reporting of all
consecutive cases diagnosed at their center. The cut-off
date for our study was 12th June 2020.2.3. Data collection
The following data were collected by clinicians on an
electronic Case Report Form: age, sex, geographical
location of patients’ residences, smoking status, body
mass index (BMI), comorbidities with the updated
Charlson Comorbidity Index (uCCI) [11], usual medi-
cation, type and status of cancer, Eastern Cooperative
Oncology Group (ECOG) performance status (PS),
anticancer therapy in the 4 weeks and in the 3 months
before the COVID-19 diagnosis respectively, the course
of the COVID-19 infection, complications and treat-
ment, especially admission to hospital and/or intensive
care unit (ICU), the need for supplemental oxygen and
mechanical ventilation and death.
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The primary end-point was all-cause mortality following
the diagnosis of COVID-19. Secondary outcomes were
admission to hospital, admission to an ICU, the need
for supplemental oxygen and the use of mechanical
ventilation during the COVID-19, and the impact of
COVID-19 on management of the cancer. The COVID-
19 severity outcome was defined as admission to an ICU
and/or use of mechanical ventilation and/or death.2.5. Statistical analysis
Analyses compared patients who died with those still
alive on June 11, 2020. Quantitative variables were
described using the usual statistics: n, mean, standard
deviation, median, interquartile range, minimum and
maximum. Qualitative variables were described using
numbers and percentages. Missing values were not
counted for percentage calculations. For quantitative
variables, groups were compared using a Student or
Wilcoxon test and for qualitative variables, using a chi2
test or a Fisher exact test.
Risk factors associated with death and their odds
ratios (ORs) were analysed using a univariate logistic
regression model. Multivariate regression was used to
estimate ORs and 95% confidence intervals (CI) for each
factor. Variables for the multivariate analysis were
selected according to their significance in the univariate
logistic regression (P < 0.05). The same analyses were
done for COVID-19 severity. We used SAS version 9.4
for the statistical analyses. The tests were all two-sided
with a 5% type one error.Fig. 1. Consor3. Results
3.1. Clinical characteristics of patients and impact of
COVID-19 on cancer treatment
From April 4 to 11th June 2020, 1354 patients from 153
institutions were registered in the national cohort data-
base. Among these patients, 1289 met the inclusion
criteria (Fig. 1): 727 patients diagnosed with COVID-19
between March 1 and April 2 were included retrospec-
tively; the remaining 562 patients were diagnosed after
April 2 and included prospectively. The diagnosis of
COVID-19 was made on the presence of detectable
SARS-CoV-2 by RT-PCR on nasopharyngeal swabs in
952 (73.8%) patients (including 294 patients who also
had images consistent with COVID-19 pneumonia on
computed tomography (CT)-scan), on only imaging
features consistent with COVID-19 pneumonia on CT-
scan in 317 (24.6%) patients and on history of highly
suggestive symptoms combined with positive SARS-
CoV-2 serology in 20 (1.6%) patients.
The participating institutions were spread over the
entire country (Fig. 2) and were general hospitals,
university hospitals, private centres and comprehen-
sive cancer centres, accounting for 31%, 28%, 25%
and 16% of cases, respectively. The median follow-up
from COVID-19 diagnosis was 34 days (95% CI:
32e36).
Patient demographics are shown in Table 1. The
median age was 67 years and 795 (62%) patients were
male. Digestive cancers were the most common type of
cancer (36%), followed by thoracic (24%) and breast
(13%) cancers and 59% of patients had a metastatict diagram.
Fig. 2. Geographic distribution of cancer patients with COVID-19 and participating institutions.
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diagnosis, 755 (59%) patients had received a systemic
anticancer treatment.
Eighty-two percent of patients experienced typical
symptoms during the course of COVID-19. The most
common symptoms were fever (52%), cough (37%) and
fatigue (26%). Gastrointestinal symptoms were identi-
fied in 12%, anosmia or ageusia were present in only 4%
and 3%, respectively. In total, 734 (65%) patients were
admitted to hospital, of whom 110 (10%) were admitted
to an ICU; 412 (42%) patients required oxygen and 49
(5%) mechanical ventilation.
In the overall cohort, only 107 (11%) patients had
their anticancer treatment modified (drug withdrawal or
change, modification of the time interval between drug
administrations) preventively before the COVID-19
infection because of the pandemic context. However,
the systemic anticancer treatment was interrupted or
stopped following the diagnosis of COVID-19 in 431
(39%) patients (Table 2).3.2. Patient outcome and risk factors for death and
COVID-19 severity
With a median follow-up of 34 days, 370 (29%) patients
had died. The death was attributable to COVID-19 in
most patients (N Z 322, 87%) and occurred after a
median of 10 days (IQR: 5e24). As shown in Table 1,
compared with survivors, patients who died were older,
more likely to be male and to be current or former
smokers, had more frequently comorbidities, long-term
or recent corticosteroids (for another reason than
COVID-19), angiotensin II antagonists (AIIA) or
angiotensin converting enzyme inhibitor (CEI) and
anticoagulant therapy as their usual medication. They
also had a poorer ECOG PS and a higher proportion of
metastatic disease and were more likely to have under-
gone cytotoxic chemotherapy in the 4 weeks or 3 months
before the COVID-19 diagnosis. The impact of immune
checkpoint inhibitors or other anticancer treatment on
the course of COVID-19 could not be analysed because
Table 1
Clinical features of the 1289 cancer patients with COVID-19.








Median (range) 67 (19e100) 70 (22e98) 66 (58e74) <0.001
<65 534 (42%) 121 (33%) 413 (45%) <0.001
65e74 430 (33%) 137 (37%) 293 (32%)
75 325 (25%) 112 (30%) 213 (23%)
Sex
Female 494 (38%) 113 (30%) 381 (41%) <0.001
Male 795 (62%) 257 (70%) 538 (59%)
Region of patient’s residencee N [ 1261 N [ 366 N [ 895
Northeast 995 (79%) 286 (78%) 709 (79%) 0.13
Southeast 100 (8%) 28 (8%) 72 (8%)
Northwest 69 (5%) 26 (7%) 43 (5%)
Southwest 75 (6%) 24 (6%) 51 (6%)
Centre 22 (2%) 2 (1%) 20 (2%)
BMI (kg/m2) N [ 1110 N [ 347 N [ 774
Median (range) 24.3 (12.1e52.7) 23.9 (13.0e43.6) 24.6 (12.1e52.7) 0.20
<18.5 101 (9.1%) 38 (11%) 63 (8%) 0.24
18.5  BMI< 25 515 (46%) 167 (48%) 348 (45%)
25  BMI< 30 311 (28%) 82 (23%) 229 (30%)
30 BMI< 35 137 (12%) 41 (12%) 96 (12%)
35 BMI< 40 32 (3%) 10 (3%) 22 (3%)
40 14 (1%) 6 (2%) 8 (1%)
Obesity (BMI  30) 183 (16%) 57 (17%) 126 (16%) 0.96
Tobacco smoking status N [ 1079 N [ 334 N [ 745
Never smoked 515 (48%) 126 (38%) 389 (52%) <0.001
Former smoker 393 (36%) 149 (44%) 244 (33%)
Current smoker 171 (16%) 59 (18%) 112 (15%)
Comorbidities, N/total
Congestive heart failure 95/1151 (8%) 45/349 (13%) 50/802 (6%) <0.001
Coronary insufficiency 99/1019 (8%) 45/328 (14%) 54/691 (8%) 0.0029
Chronic obstructive pulmonary disease 124/1020 (12%) 55/328 (17%) 69/692 (10%) 0.0019
Diabetes 241/1151 (21%) 84/349 (24%) 157/796 (20%) 0.08
Hypertension 529/1151 (46%) 189/349 (54%) 340/802 (42%) 0.0002
Number of comorbidities N [ 1289 N [ 370 N [ 919
0 175 (14%) 21 (6%) 154 (17%)
1 280 (22%) 48 (13%) 232 (25%) <0.001
2 294 (23%) 87 (23%) 207 (22%)
3 216 (17%) 79 (21%) 137 (15%)
4 324 (25%) 135 (36%) 189 (21%)
Updated Charlson comorbidity index N [ 932 N [ 299 N [ 633
0e3 284 (30%) 56 (19%) 228 (36%) <0.001
4 648 (70%) 243 (81%) 405 (64%)
Usual medicationd, N/total
Long-term corticosteroids 131/1141 (11%) 51/344 (15%) 80/797 (10%) 0.02
Transient corticosteroids (ongoing or  4 weeks) 46/1011 (4%) 24/323 (7%) 22/688 (3%) 0.003
NSAIDs 40/1142 (3%) 17/345 (4.9%) 23/797 (2.9%) 0.08
Immunosuppressive therapy 35/1012 (3%) 11/324 (3%) 24/688 (3%) 0.94
CEI or AIIA 222/1143 (19%) 81/346 (23%) 141/797 (18%) 0.02
Anticoagulant therapy 358/1140 (31%) 141/344 (41%) 217 (796 (27%)) <0.001
History of Cancer
Cancer type N [ 1287 N [ 370 N [ 919
Digestivea 470 (36%) 146 (39%) 324 (35%) <0.001
Thoracicb 311 (24%) 113 (30%) 198 (22%)
Gynaecological 252 (20%) 44 (12%) 208 (22%)
Breast Cancer 173 (68.7%) 26 (59.1%) 147 (70.7%)
Other gynaecologicalc 79 (31.3%) 18 (40.9%) 61 (29.3%)
Head and neck 104 (8%) 22 (6%) 82 (9%)
Central nervous system 65 (5%) 19 (5%) 46 (5%)
Genitourinary 65 (5%) 21 (6%) 44 (5%)
Dermatological 14 (1%) 3 (1%) 11 (1%)
Others 6 (<1%) 2 (<1%) 4 (<1%)
(continued on next page)
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Cancer stage N [ 1285 N [ 370 N [ 915
Metastatic 758 (59%) 252 (68%) 506 (55%) <0.001
Localised 527 (41%) 118 (32%) 409 (45%)
Time since cancer diagnosis N [ 1134 N [ 343 N [ 791
<1 year 597 (53%) 176 (51%) 421 (53%) 0.79
1e3 years 290 (25%) 92 (27%) 198 (25%)
3 years 247 (22%) 75 (22%) 172 (22%)
ECOG PS before COVID-19 diagnosis N [ 931 N [ 294 N [ 637
0 182 (20%) 20 (7%) 162 (25%) <0.001
1 365 (39%) 88 (30%) 277 (44%)
2 247 (26%) 104 (35%) 143 (22%)
3e4 137 (15%) 82 (28%) 55 (9%)
Anticancer treatment during 4 weeks before COVID-19 diagnosis
Systemic therapy 491 (38%) 151 (41%) 340 (37%) 0.202
cytotoxic chemotherapy 385 (30%) 126 (34%) 259 (28%) 0.03
immunotherapy 62 (5%) 22 (6%) 40 (4%) 0.23
targeted therapy 114 (9%) 28 (8%) 86 (9%) 0.31
hormone therapy 27 (2%) 5 (1%) 22 (2%) 0.23
local therapy, N/total
radiotherapy 95/1262 (7%) 30/357 (8%) 65/905 (7%) 0.45
surgery 56/1289 (4%) 12/370 (3%) 44/919 (5%) 0.61
Anticancer treatment during 3 months before COVID-19 diagnosis
Systemic therapy 755 (59%) 224 (61%) 531 (58%) 0.36
cytotoxic chemotherapy 577 (45%) 183 (49%) 394 (43%) 0.03
immunotherapy 110 (8%) 40 (11%) 70 (8%) 0.06
targeted therapy 181 (14%) 42 (11%) 139 (15%) 0.08
hormone therapy 57 (4%) 10 (3%) 47 (5%) 0.06
local therapy, N/total
radiotherapy 133/1289 (10%) 48/370 (13%) 85/919 (9.2%) 0.047
surgery 56/1289 (4%) 12/370 (3%) 44/919 (5%) 0.22
COVID-19 treatment
Admission to hospital 734/1125 (65%) 291/341 (85%) 443/784 (57%) <0.001
Admission to ICU 110/1125 (10%) 62/341 (18%) 48/784 (6%) <0.001
Oxygen therapy 412/984 (42%) 208/316 (66%) 204/668 (31%) <0.001
Mechanical ventilation 49/989 (5%) 27/320 (8%) 22/669 (3%) 0.0005
AIIA: angiotensin II antagonists, BMI: body mass index, CEI: converting enzyme inhibitor, NSAIDs: non-steroidal anti-inflammatory drugs, PS:
performance status.
a Digestive tumours: colorectal (N Z 185, 14.3%), pancreas (N Z 86, 6.7%), stomach (N Z 50, 3.8%), oesophagus (N Z 42, 3.2%), liver
(N Z 34, 2.6%), others (digestive neuroendocrine, biliary tract, anus, peritoneum, small intestine, appendix, gastrointestinal stromal tumour,
others) (N Z 73, 5.7%).
b Thoracic tumours: non-small cell lung carcinoma (N Z 233,18%), small cell lung carcinoma (N Z 26, 1.9%), mesothelioma and others
(N Z 52, 4%).
c Gynaecological tumours: ovary (N Z 37, 2.8%), cervix (N Z 17, 1.3%), endometrium (N Z 15, 1.2%), others (N Z 10, 0.7%).
d Before COVID-19 diagnosis.
e Northeast: Hauts-de-France, Paris/ı̂le-de-France, Grand-Est, Bourgogne-France-Comté; Southeast: Auvergne-Rhône-Alpes, Provence-Alpes-
Côte d’Azur; Northwest: Normandie, Bretagne, Pays de la Loire; Southwest: Nouvelle-Aquitaine, Occitanie; Centre: Centre-Val de Loire.
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treatments.
The association between prognostic parameters and
all-cause mortality are shown in Supplementary Table 1
and Fig. 3. In univariate analysis, age, sex, the ECOG
PS, the updated Charlson comorbidity index, smoking
status, thoracic primary tumour location, metastatic
tumour stage, lung metastases, cytotoxic chemotherapy
during the 3 months before the COVID-19 diagnosis,
corticosteroids before the COVID-19 diagnosis, antico-
agulant therapy, converting enzyme inhibitor (CEI) or
angiotensin II antagonist (AIIA), and admission to
anICU were significantly associated with an increasedrisk of death. In the multivariate analysis sex, the ECOG
PS, the uCCI and admission to an ICU remained sta-
tistically significant risk factors for death. Age, smoking
status and corticosteroids before the COVID-19 diag-
nosis also showed a statistically non-significant
increased risk of death. Importantly, the administra-
tion of cytotoxic chemotherapy in the 3 months before
COVID-19 diagnosis was not associated with an
increased risk of death.
Overall, 424 (33%) patients had a severe form of
COVID-19 defined by admission to an ICU and/or
mechanical ventilation and/or death but only 129 (9%)
patients were admitted to ICU and/or had mechanical
Table 2
Modification or interruption of anticancer treatments because of
COVID-19 diagnosis.
Anticancer treatment Type of modification Number
(%)
Systemic therapy N [ 1092
Modification of the regimen 53 (5%)
Temporary interruption 321 (29%)
Definitive interruption 110 (10%)
Radiotherapy N [ 1093
Cancellation 1 (<1%)




Definitive interruption 13 (1%)
Surgery N [ 1095
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died without a previous admission to ICU or a me-
chanical ventilation. The association between prognostic
parameters and COVID-19 severity are shown in
Supplementary Table 2 and Fig. 4. In univariate anal-
ysis, age, sex, the ECOG PS, the uCCI, smoking status,
thoracic primary tumour location, metastatic tumour
stage, lung metastases, cytotoxic chemotherapy duringFig. 3. Forest plot of the multivariate analysis of factors associated wi
with COVID-19.the 3 months before the COVID-19 diagnosis, cortico-
steroids before the COVID-19 diagnosis, anticoagulant
therapy, and CEI or AIIA were significantly associated
with COVID-19 severity. In the multivariate, sex, the
ECOG PS, the updated Charlson Comorbidity Index
(uCCI), corticosteroids before the COVID-19 diagnosis
and thoracic primary tumour location remained inde-
pendent predictors of COVID-19 severity. Age was
associated with a statistically non-significant increase in
the risk of death either. Again, the administration of
cytotoxic chemotherapy in the 3 months before COVID-
19 diagnosis was not associated with COVID-19
severity.
When the multivariate analysis was restricted only to
patients with RT-PCR-documented SARS-CoV-2
(n Z 952), ECOG PS, uCCI and ICU admission
remained statistically significant risk factors for death,
as were age, smoking status and cytotoxic chemotherapy
administered within 3 months before the COVID-19
diagnosis (Supplementary Table 3). The ECOG PS and
the uCCI were the only independent predictors of
COVID-19 severity (Supplementary Table 4).4. Discussion
After starting in December 2019 in Wuhan, China, the
COVID-19 epidemic quickly spread to Europe in March
2020 and then to the rest of the world with a speed that
shook saturated healthcare systems unprepared for such
a pandemic. In the wake of a small Chinese studyth all-cause mortality in the overall cohort of 1289 cancer patients
Fig. 4. Forest plot of the multivariate analysis of factors associated with COVID-19 severity outcome defined by admission to ICU and/or
mechanical ventilation and/or death in the overall cohort of 1289 cancer patients with COVID-19.
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severe respiratory complications related to SARS-CoV-
2 infection and that patients with the highest risk were
those who had received chemotherapy or surgery in the
month preceding the infection [1], the medical commu-
nity began to modify various practices in the treatment
of cancer during the COVID-19 pandemic. The main
objectives of these changes were to avoid very high-risk
situations such as surgery or intensive cytotoxic
chemotherapy and to minimise patients’ exposure to
SARS-CoV-2.
For these reasons, in France, the French health au-
thority published on March 11, 2020 guidelines to pro-
tect patients with cancer against SARS-CoV-2 infection
[12]. Then, another study in Wuhan reported that cancer
patients who had received their last anticancer treatment
during the 14 days before the diagnosis of COVID-19
had an increased risk of experiencing severe events
[13]. In this context, international and national panels
recommended delaying or suspending anticancer treat-
ments, when feasible, thereby raising the issue of po-
tential cancer progression [14e22]. We created a
national multicentre cohort in order to better under-
stand the risk factors for mortality and severity of
COVID-19, particularly the impact of various anti-
cancer treatments, in order to determine the best prac-
tices and to help clinicians in their decision-making, and
to assess the impact of COVID-19 on anticancer
treatments.First, our results show that the mortality rate in
cancer patients with COVID-19 is far higher (29%) than
that in COVID-19 patients overall [23,24]. To date, all
studies that have included a significant number of cancer
patients with COVID-19 have reported a mortality rate
>10%. However, this rate is very variable between
studies [4e9,25e28], ranging from 11% to 12% [5,25,28]
to 28% in two studies, including the United Kingdom
(UK) Coronavirus Cancer Monitoring Project
(UKCCMP) cohort that included 800 patients [4,8]. Of
note, the highest mortality rate published to date (33%)
comes from the international cohort of patients with
thoracic cancers and COVID-19 (TERAVOLT) [26]. In
our cohort, the 311 patients with thoracic cancer had a
mortality rate of 36%, which was the highest mortality
rate of all tumour locations. The variations in mortality
rates observed between studies could be explained, in
part, by disparities in the proportions of patients with
significant comorbidities or poor PS and in the pro-
portions of the different types of tumours, as well as
differences in the use of intensive care resources. It may
also depend on hospital admission criteria to secondary
care. In some countries, like in the US, a lower threshold
is likely to exist and mild or asymptomatic patients
might be admitted. A plausible explanation for the high
mortality rate observed in our cohort is both its larger
size, and the ’selection bias’, leading to a greater likeli-
hood of registering patients with adverse COVID-19
outcomes, while cancer patients with less severe
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since not consulting during this period of time. Thus, the
patients included in the French cohort were mainly
hospitalized patients with most often symptomatic
COVID-19 and thus probably more severe. Similarly, it
is possible that at the time of the analysis some infor-
mation may have been missing, especially in cases of
ambulatory care for diseases with a benign course. The
relatively low rate of ICU transfer (10%) in our cancer
patients compared to others studies [7,9,13,27,28] could
be explained by a general ICU policy, since all ICU
departments in areas of high COVID-19 incidence in
France were overwhelmed at that period, with a lack of
available ICU beds. Patients without severe comorbid-
ities were thus prioritized for ICU admission, and cancer
patients with their underlying comorbidities could have
been excluded from intensive care. However similar
rates of ICU transfer (7% and 10% respectively) have
been reported in the UKCCMP and TERAVOLT
studies [8,26], probably for the same reasons. Retro-
spectively, the relevance of such triage strategy raises an
ethical question and one can legitimately wonder
whether these policies should continue in the event of a
second wave, during which a better organization of
intensive care access is to be hoped for.
We confirm the risk factors for death that have
already been reported in previous studies, such as male
sex, the ECOG PS or the presence of comorbidities,
including cardiovascular disease, hypertension or
chronic obstructive pulmonary disease (COPD) [4,6e9].
One point that remains unclear is the impact of cancer
treatments on the severity of COVID-19 and its mor-
tality. According to our analysis, the recent adminis-
tration of cytotoxic chemotherapy was not a significant
risk factor for death in the overall cohort but slightly
increased the risk of death in the sub-population of RT-
PCR positive patients, at the limit of significance
(ORZ 1.53 95%CI: 1.00e2.34; pZ 0.05). The results in
the literature are very discordant in this regard. Two
Chinese studies showed that recent cytotoxic chemo-
therapy was associated with increased mortality [6,9].
However, more recent results from the two large cohorts
of cancer patients in the UK and the United States of
America (USA) [7,8] and from the TERAVOLT cohort
of patients with thoracic cancers [26] concluded that
chemotherapy had no effect on COVID-19-related
mortality. Added to these last data, our results suggest
that chemotherapy should be continued in confirmed
SARS-CoV-2-negative patients during the pandemic,
without significantly endangering the patient, but this
would need to be confirmed on larger series, encour-
aging us to promote collaborative projects pooling data
from different cohorts.
As recently reported in the two cohorts in the UK
and US [7,8], we found no association between mortality
and the recent administration of non-cytotoxic systemic
anticancer treatments, whether immunotherapy,targeted therapy or hormone therapy. Immunotherapy
did not worsen outcomes for patients with COVID-19 in
other studies, including two studies dedicated to patients
with thoracic cancer [26e28]. However, the role of
immunotherapy as a risk factor or not for COVID-19
severity or mortality remains to be clarified given the
contradictory data from two previous Chinese studies
reporting an increased risk of death or of severe disease
with recent immunotherapy [6,25]. Recent case reports
have suggested that it is safe to maintain targeted ther-
apy with ALK/ROS1 tyrosine kinase inhibitors in non-
small cell lung cancer (NSCLC) patients with asymp-
tomatic SARS-CoV-2 interstitial pneumonia. This is
important as there is a high risk of a cancer flare-up
following discontinuation of such a treatment, with a
rapidly progressive adverse cancer course leading to
death [29].
One of the objectives of our cohort was to analyse the
impact of a COVID-19 diagnosis on cancer treatment.
We found that COVID-19 was responsible for a tem-
porary or definitive interruption of cytotoxic chemo-
therapy in 39% of patients and a change in the
chemotherapy regimen in 5% of cases. We do not have
sufficient hindsight to measure the consequences of these
therapeutic modifications, but in the future, it will be
essential to determine whether COVID-19-related
changes in treatment were responsible for faster cancer
progression and shorter survival.
The GCO-002 CACOVID cohort has some limita-
tions. First, the diagnosis of COVID-19 was mainly
made by RT-PCR and/or CT-scan. Due to their limited
availability in France during the early phase of the
pandemic, RT-PCR were reserved for patients with
suggestive symptoms and therefore not carried out sys-
tematically throughout the country, even in vulnerable
populations. This, added to the estimated 20e30% of
false-negatives, probably contributed not only to an
underestimation of the number of patients with COVID-
19, as it was recently demonstrated [30], but also to an
overestimation of the proportion of severe forms of
COVID-19 since included patients were necessarily
symptomatic and/or hospitalized. As the first part of the
cohort was retrospective, some data were missing, but
the database completion rate was 85% for the majority
of the parameters. Finally, the study does not provide an
estimate of COVID-19 prevalence in cancer patients
since we do not yet have the total number of cancer
patients followed during the study period.
Despite these weaknesses, the cohort has strengths.
To our knowledge, it is the largest cohort of cancer
patients with COVID-19 to date. It covers the entire
national territory and perfectly reflects the epidemiology
of SARS-CoV-2 infection in France since the geographic
distribution of cancer patients with COVID-19 is similar
to that of all infected patients in the country, the most
affected regions being Greater Paris, and the Northeast
and Southeast of France.
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mortality in cancer patients with COVID-19 is high and
is associated with general characteristics of patients. Age
Patients receiving corticosteroids before COVID-19
diagnosis and patients with thoracic cancers had also
more severe COVID-19. We found no deleterious effects
of recent cytotoxic chemotherapy, except in the sub-
group of patients with PCR-detected SARS-CoV-2
RNA. This suggests that cytotoxic treatments should be
continued in SARS-CoV-2-negative patients during the
pandemic, without significantly endangering the patient
although such recommendation deserves to be
confirmed on larger series. In almost 40% of patients,
the systemic anticancer therapy was interrupted or
stopped after COVID-19 diagnosis. The impact of these
interruptions on cancer evolution will be evaluated in
the future, as well as the impact of social inequalities on
the severity and management of COVID-19 infections.
Author contributions section
AL, AT, IRC, KLM, JT, OB, ACHB, DD, GZ and TA
conceived and designed the study. AL and KLM
designed the statistical analysis plan, analysed the data
and developed the figures and tables. All authors, except
for KLM and XP, coordinated data contributions at
their respective sites and provided patients’ data.
All authors contributed intellectual content during
the drafting and revision of the work and approved the
final version.
Funding support
The study was funded and coordinated by the FFCD.
ANOCEF-IGCNO, ARCAGY-GINECO, FFCD,
GERCOR, GORTEC/intergroupe ORL, and IFCT
were responsible for the study design, data collection,
data interpretation, and writing the report. The FFCD
was responsible for database management and the sta-
tistical analysis. The corresponding authors had full
access to the data and had final responsibility for the
decision to submit for publication.
Role of the funding sources
The funding sources had no role in the preparation
and finalisation of the manuscript.Conflict of interest statement
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LACHAIER Emma (AMIENS CHU HÔPITAL SUD);
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SUD - Service d’Oncologie médicale); Dr MOREIRA
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CHIVE Emilie (AMIENS CHU HOPITAL SUD -
Service de chirurgie digestive); POULET-
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GRReCC); CHARIFI-ALAOUI Ikram (DIJON CAC
GF LECLERC); Pr GHIRINGHELLI François
(DIJON CAC Service Oncologie Médicale); Dr
DROUILLARD Antoine (DIJON CHU François
Mitterrand - Service d’HGE); Dr CHAIX MARIE
(DIJON CHU François Mitterrand - Service d’HGE);
Pr MANFREDI Sylvain (DIJON CHU François Mit-
terrand - Service d’HGE); Pr LEPAGE Côme (DIJON
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Véronique (GRENOBLE Clinique privée GHM Institut
DANIEL HOLLARD - Service d’Oncologie); THOOR
Audrey (GRENOBLE CHU GRENOBLE ALPES -
Service d’HGE); JACQUET Emanuelle (GRENOBLE
CHU GRENOBLE ALPES - Service d’oncologie et
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EDOUARD HERRIOT - Service d’Oncologie Médi-
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CONFLUENT SAS - Service Oncologie Médicale);
HUGON Nathalie (NANTES Hopital Privé
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Hopital Privé CONFLUENT SAS - Centre de recherche
clinique); Dr LORTHOLARY Alain (NANTES Hopi-
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